SPAG5 and estrogen-receptor negative breast cancer: SPAG5 might be an independent prognostic and predictive biomarker that may have clinical utility as a biomarker for combination cytotoxic chemotherapy sensitivity, especially in estrogen receptor-negative breast cancer [16].